Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study
Hribernik, Nezka, Strasek, Katja, Huff, Daniel T, Studen, Andrej, Zevnik, Katarina, Skalic, Katja, Jeraj, Robert, Rebersek, Martina
![[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647355c34e662f30ba53aa2a/cover-image.jpg)
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
Valentinuzzi, Damijan, Vrankar, Martina, Boc, Nina, Ahac, Valentina, Zupancic, Ziga, Unk, Mojca, Skalic, Katja, Zagar, Ivana, Studen, Andrej, Simoncic, Urban, Eickhoff, Jens, Jeraj, Robert
Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy
Hribernik, Nezka, Strasek, Katja, Studen, Andrej, Zevnik, Katarina, Skalic, Katja, Jeraj, Robert, Rebersek, Martina